Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy
To investigate the relationship between subfoveal choroidal thickness, choroidal vascular hyperpermeability, and complement factor H (CFH) gene polymorphism in typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). Fifty-eight patients with typical AMD and 63 pat...
Gespeichert in:
| Veröffentlicht in: | Investigative ophthalmology & visual science 2012-06, Vol.53 (7), p.3663-3672 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3672 |
|---|---|
| container_issue | 7 |
| container_start_page | 3663 |
| container_title | Investigative ophthalmology & visual science |
| container_volume | 53 |
| creator | Jirarattanasopa, Pichai Ooto, Sotaro Nakata, Isao Tsujikawa, Akitaka Yamashiro, Kenji Oishi, Akio Yoshimura, Nagahisa |
| description | To investigate the relationship between subfoveal choroidal thickness, choroidal vascular hyperpermeability, and complement factor H (CFH) gene polymorphism in typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
Fifty-eight patients with typical AMD and 63 patients with PCV underwent fluorescein angiography, indocyanine green angiography (IA), and spectral-domain optical coherence tomography (OCT) using enhanced depth imaging (EDI). Subfoveal choroidal thickness was measured using EDI-OCT images, and choroidal hyperpermeability was evaluated using late-phase IA images. The major AMD-associated single-nucleotide polymorphisms were genotyped in 86 patients.
Mean subfoveal choroidal thickness was significantly lower in eyes with typical AMD than that in eyes with PCV (P = 0.025). Subfoveal choroidal thickness was greater in eyes with choroidal hyperpermeability than that in eyes without it in typical AMD (P < 0.001) and PCV (P = 0.020), and in the fellow eyes of typical AMD (P < 0.001) and PCV (P = 0.027). In eyes without choroidal hyperpermeability, the mean subfoveal choroidal thickness was greater in PCV than that in typical AMD (P = 0.001). Choroidal thickness decreased after photodynamic therapy combined with intravitreal ranibizumab in typical AMD (P = 0.016) and PCV (P = 0.036). In eyes with PCV, the I62V polymorphism in the CFH gene contributed to choroidal thickness (P = 0.043).
Choroidal thickness is related to the AMD subtypes, choroidal hyperpermeability, and I62V CFH gene polymorphism. In eyes without choroidal hyperpermeability, EDI-OCT is useful as an auxiliary measure for differentiating typical AMD and PCV. |
| doi_str_mv | 10.1167/iovs.12-9619 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1021126198</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1021126198</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-9814069e60ef5ec70cc04cbca5dd007558810f1aac7ca059e0b326ffb688d5fc3</originalsourceid><addsrcrecordid>eNpNkUtPwzAQhC0EouVx44x85NCA7eA8jqgCilSJC5yjjbOhBicOtlspf4NfTNqUCmml3cO3M9IMIVec3XKepHfabvwtF1Ge8PyITLmUIpJpFh__uyfkzPtPxgTngp2SiRAyZbEUU_IzX1lndQWGhpVWXy16P6Mb8GptwNFV36EbpkEotdGhn1FoK6ps0xlssA20BhWsowuqWwofGDk0ELCiDYwKFX5giw6Ctu3ut7Om70ZHdfAeDW0HYdVfkJMajMfL_T4n70-Pb_NFtHx9fpk_LCMVyzREecbvWZJjwrCWqFKmFLtXpQJZVYylUmYZZzUHUKkCJnNkZSySui6TLKtkreJzcjPqds5-r9GHotFeoTHQol37gu_iGlLNBnQ2ospZ7x3WRed0A64foGLbQrFtoeCi2LYw4Nd75XXZYHWA_2KPfwGpmIfH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1021126198</pqid></control><display><type>article</type><title>Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Jirarattanasopa, Pichai ; Ooto, Sotaro ; Nakata, Isao ; Tsujikawa, Akitaka ; Yamashiro, Kenji ; Oishi, Akio ; Yoshimura, Nagahisa</creator><creatorcontrib>Jirarattanasopa, Pichai ; Ooto, Sotaro ; Nakata, Isao ; Tsujikawa, Akitaka ; Yamashiro, Kenji ; Oishi, Akio ; Yoshimura, Nagahisa</creatorcontrib><description>To investigate the relationship between subfoveal choroidal thickness, choroidal vascular hyperpermeability, and complement factor H (CFH) gene polymorphism in typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
Fifty-eight patients with typical AMD and 63 patients with PCV underwent fluorescein angiography, indocyanine green angiography (IA), and spectral-domain optical coherence tomography (OCT) using enhanced depth imaging (EDI). Subfoveal choroidal thickness was measured using EDI-OCT images, and choroidal hyperpermeability was evaluated using late-phase IA images. The major AMD-associated single-nucleotide polymorphisms were genotyped in 86 patients.
Mean subfoveal choroidal thickness was significantly lower in eyes with typical AMD than that in eyes with PCV (P = 0.025). Subfoveal choroidal thickness was greater in eyes with choroidal hyperpermeability than that in eyes without it in typical AMD (P < 0.001) and PCV (P = 0.020), and in the fellow eyes of typical AMD (P < 0.001) and PCV (P = 0.027). In eyes without choroidal hyperpermeability, the mean subfoveal choroidal thickness was greater in PCV than that in typical AMD (P = 0.001). Choroidal thickness decreased after photodynamic therapy combined with intravitreal ranibizumab in typical AMD (P = 0.016) and PCV (P = 0.036). In eyes with PCV, the I62V polymorphism in the CFH gene contributed to choroidal thickness (P = 0.043).
Choroidal thickness is related to the AMD subtypes, choroidal hyperpermeability, and I62V CFH gene polymorphism. In eyes without choroidal hyperpermeability, EDI-OCT is useful as an auxiliary measure for differentiating typical AMD and PCV.</description><identifier>ISSN: 1552-5783</identifier><identifier>EISSN: 1552-5783</identifier><identifier>DOI: 10.1167/iovs.12-9619</identifier><identifier>PMID: 22570352</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Antibodies, Monoclonal, Humanized - administration & dosage ; Capillary Permeability - physiology ; Choroid - blood supply ; Choroid - metabolism ; Choroid - pathology ; Choroidal Neovascularization - drug therapy ; Choroidal Neovascularization - genetics ; Choroidal Neovascularization - pathology ; Complement Factor H - genetics ; Complement Factor H - metabolism ; DNA - genetics ; Female ; Fluorescein Angiography ; Fundus Oculi ; Genetic Predisposition to Disease ; Genotype ; Humans ; Hypertrophy ; Intravitreal Injections ; Macular Degeneration - drug therapy ; Macular Degeneration - genetics ; Macular Degeneration - pathology ; Male ; Ophthalmoscopy ; Photochemotherapy ; Polymorphism, Single Nucleotide ; Prognosis ; Ranibizumab ; Tomography, Optical Coherence ; Visual Acuity</subject><ispartof>Investigative ophthalmology & visual science, 2012-06, Vol.53 (7), p.3663-3672</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-9814069e60ef5ec70cc04cbca5dd007558810f1aac7ca059e0b326ffb688d5fc3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22570352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jirarattanasopa, Pichai</creatorcontrib><creatorcontrib>Ooto, Sotaro</creatorcontrib><creatorcontrib>Nakata, Isao</creatorcontrib><creatorcontrib>Tsujikawa, Akitaka</creatorcontrib><creatorcontrib>Yamashiro, Kenji</creatorcontrib><creatorcontrib>Oishi, Akio</creatorcontrib><creatorcontrib>Yoshimura, Nagahisa</creatorcontrib><title>Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy</title><title>Investigative ophthalmology & visual science</title><addtitle>Invest Ophthalmol Vis Sci</addtitle><description>To investigate the relationship between subfoveal choroidal thickness, choroidal vascular hyperpermeability, and complement factor H (CFH) gene polymorphism in typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
Fifty-eight patients with typical AMD and 63 patients with PCV underwent fluorescein angiography, indocyanine green angiography (IA), and spectral-domain optical coherence tomography (OCT) using enhanced depth imaging (EDI). Subfoveal choroidal thickness was measured using EDI-OCT images, and choroidal hyperpermeability was evaluated using late-phase IA images. The major AMD-associated single-nucleotide polymorphisms were genotyped in 86 patients.
Mean subfoveal choroidal thickness was significantly lower in eyes with typical AMD than that in eyes with PCV (P = 0.025). Subfoveal choroidal thickness was greater in eyes with choroidal hyperpermeability than that in eyes without it in typical AMD (P < 0.001) and PCV (P = 0.020), and in the fellow eyes of typical AMD (P < 0.001) and PCV (P = 0.027). In eyes without choroidal hyperpermeability, the mean subfoveal choroidal thickness was greater in PCV than that in typical AMD (P = 0.001). Choroidal thickness decreased after photodynamic therapy combined with intravitreal ranibizumab in typical AMD (P = 0.016) and PCV (P = 0.036). In eyes with PCV, the I62V polymorphism in the CFH gene contributed to choroidal thickness (P = 0.043).
Choroidal thickness is related to the AMD subtypes, choroidal hyperpermeability, and I62V CFH gene polymorphism. In eyes without choroidal hyperpermeability, EDI-OCT is useful as an auxiliary measure for differentiating typical AMD and PCV.</description><subject>Aged</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Capillary Permeability - physiology</subject><subject>Choroid - blood supply</subject><subject>Choroid - metabolism</subject><subject>Choroid - pathology</subject><subject>Choroidal Neovascularization - drug therapy</subject><subject>Choroidal Neovascularization - genetics</subject><subject>Choroidal Neovascularization - pathology</subject><subject>Complement Factor H - genetics</subject><subject>Complement Factor H - metabolism</subject><subject>DNA - genetics</subject><subject>Female</subject><subject>Fluorescein Angiography</subject><subject>Fundus Oculi</subject><subject>Genetic Predisposition to Disease</subject><subject>Genotype</subject><subject>Humans</subject><subject>Hypertrophy</subject><subject>Intravitreal Injections</subject><subject>Macular Degeneration - drug therapy</subject><subject>Macular Degeneration - genetics</subject><subject>Macular Degeneration - pathology</subject><subject>Male</subject><subject>Ophthalmoscopy</subject><subject>Photochemotherapy</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Prognosis</subject><subject>Ranibizumab</subject><subject>Tomography, Optical Coherence</subject><subject>Visual Acuity</subject><issn>1552-5783</issn><issn>1552-5783</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkUtPwzAQhC0EouVx44x85NCA7eA8jqgCilSJC5yjjbOhBicOtlspf4NfTNqUCmml3cO3M9IMIVec3XKepHfabvwtF1Ge8PyITLmUIpJpFh__uyfkzPtPxgTngp2SiRAyZbEUU_IzX1lndQWGhpVWXy16P6Mb8GptwNFV36EbpkEotdGhn1FoK6ps0xlssA20BhWsowuqWwofGDk0ELCiDYwKFX5giw6Ctu3ut7Om70ZHdfAeDW0HYdVfkJMajMfL_T4n70-Pb_NFtHx9fpk_LCMVyzREecbvWZJjwrCWqFKmFLtXpQJZVYylUmYZZzUHUKkCJnNkZSySui6TLKtkreJzcjPqds5-r9GHotFeoTHQol37gu_iGlLNBnQ2ospZ7x3WRed0A64foGLbQrFtoeCi2LYw4Nd75XXZYHWA_2KPfwGpmIfH</recordid><startdate>20120614</startdate><enddate>20120614</enddate><creator>Jirarattanasopa, Pichai</creator><creator>Ooto, Sotaro</creator><creator>Nakata, Isao</creator><creator>Tsujikawa, Akitaka</creator><creator>Yamashiro, Kenji</creator><creator>Oishi, Akio</creator><creator>Yoshimura, Nagahisa</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120614</creationdate><title>Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy</title><author>Jirarattanasopa, Pichai ; Ooto, Sotaro ; Nakata, Isao ; Tsujikawa, Akitaka ; Yamashiro, Kenji ; Oishi, Akio ; Yoshimura, Nagahisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-9814069e60ef5ec70cc04cbca5dd007558810f1aac7ca059e0b326ffb688d5fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Capillary Permeability - physiology</topic><topic>Choroid - blood supply</topic><topic>Choroid - metabolism</topic><topic>Choroid - pathology</topic><topic>Choroidal Neovascularization - drug therapy</topic><topic>Choroidal Neovascularization - genetics</topic><topic>Choroidal Neovascularization - pathology</topic><topic>Complement Factor H - genetics</topic><topic>Complement Factor H - metabolism</topic><topic>DNA - genetics</topic><topic>Female</topic><topic>Fluorescein Angiography</topic><topic>Fundus Oculi</topic><topic>Genetic Predisposition to Disease</topic><topic>Genotype</topic><topic>Humans</topic><topic>Hypertrophy</topic><topic>Intravitreal Injections</topic><topic>Macular Degeneration - drug therapy</topic><topic>Macular Degeneration - genetics</topic><topic>Macular Degeneration - pathology</topic><topic>Male</topic><topic>Ophthalmoscopy</topic><topic>Photochemotherapy</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Prognosis</topic><topic>Ranibizumab</topic><topic>Tomography, Optical Coherence</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jirarattanasopa, Pichai</creatorcontrib><creatorcontrib>Ooto, Sotaro</creatorcontrib><creatorcontrib>Nakata, Isao</creatorcontrib><creatorcontrib>Tsujikawa, Akitaka</creatorcontrib><creatorcontrib>Yamashiro, Kenji</creatorcontrib><creatorcontrib>Oishi, Akio</creatorcontrib><creatorcontrib>Yoshimura, Nagahisa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Investigative ophthalmology & visual science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jirarattanasopa, Pichai</au><au>Ooto, Sotaro</au><au>Nakata, Isao</au><au>Tsujikawa, Akitaka</au><au>Yamashiro, Kenji</au><au>Oishi, Akio</au><au>Yoshimura, Nagahisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy</atitle><jtitle>Investigative ophthalmology & visual science</jtitle><addtitle>Invest Ophthalmol Vis Sci</addtitle><date>2012-06-14</date><risdate>2012</risdate><volume>53</volume><issue>7</issue><spage>3663</spage><epage>3672</epage><pages>3663-3672</pages><issn>1552-5783</issn><eissn>1552-5783</eissn><abstract>To investigate the relationship between subfoveal choroidal thickness, choroidal vascular hyperpermeability, and complement factor H (CFH) gene polymorphism in typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
Fifty-eight patients with typical AMD and 63 patients with PCV underwent fluorescein angiography, indocyanine green angiography (IA), and spectral-domain optical coherence tomography (OCT) using enhanced depth imaging (EDI). Subfoveal choroidal thickness was measured using EDI-OCT images, and choroidal hyperpermeability was evaluated using late-phase IA images. The major AMD-associated single-nucleotide polymorphisms were genotyped in 86 patients.
Mean subfoveal choroidal thickness was significantly lower in eyes with typical AMD than that in eyes with PCV (P = 0.025). Subfoveal choroidal thickness was greater in eyes with choroidal hyperpermeability than that in eyes without it in typical AMD (P < 0.001) and PCV (P = 0.020), and in the fellow eyes of typical AMD (P < 0.001) and PCV (P = 0.027). In eyes without choroidal hyperpermeability, the mean subfoveal choroidal thickness was greater in PCV than that in typical AMD (P = 0.001). Choroidal thickness decreased after photodynamic therapy combined with intravitreal ranibizumab in typical AMD (P = 0.016) and PCV (P = 0.036). In eyes with PCV, the I62V polymorphism in the CFH gene contributed to choroidal thickness (P = 0.043).
Choroidal thickness is related to the AMD subtypes, choroidal hyperpermeability, and I62V CFH gene polymorphism. In eyes without choroidal hyperpermeability, EDI-OCT is useful as an auxiliary measure for differentiating typical AMD and PCV.</abstract><cop>United States</cop><pmid>22570352</pmid><doi>10.1167/iovs.12-9619</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1552-5783 |
| ispartof | Investigative ophthalmology & visual science, 2012-06, Vol.53 (7), p.3663-3672 |
| issn | 1552-5783 1552-5783 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1021126198 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Aged Antibodies, Monoclonal, Humanized - administration & dosage Capillary Permeability - physiology Choroid - blood supply Choroid - metabolism Choroid - pathology Choroidal Neovascularization - drug therapy Choroidal Neovascularization - genetics Choroidal Neovascularization - pathology Complement Factor H - genetics Complement Factor H - metabolism DNA - genetics Female Fluorescein Angiography Fundus Oculi Genetic Predisposition to Disease Genotype Humans Hypertrophy Intravitreal Injections Macular Degeneration - drug therapy Macular Degeneration - genetics Macular Degeneration - pathology Male Ophthalmoscopy Photochemotherapy Polymorphism, Single Nucleotide Prognosis Ranibizumab Tomography, Optical Coherence Visual Acuity |
| title | Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T19%3A24%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Choroidal%20thickness,%20vascular%20hyperpermeability,%20and%20complement%20factor%20H%20in%20age-related%20macular%20degeneration%20and%20polypoidal%20choroidal%20vasculopathy&rft.jtitle=Investigative%20ophthalmology%20&%20visual%20science&rft.au=Jirarattanasopa,%20Pichai&rft.date=2012-06-14&rft.volume=53&rft.issue=7&rft.spage=3663&rft.epage=3672&rft.pages=3663-3672&rft.issn=1552-5783&rft.eissn=1552-5783&rft_id=info:doi/10.1167/iovs.12-9619&rft_dat=%3Cproquest_cross%3E1021126198%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1021126198&rft_id=info:pmid/22570352&rfr_iscdi=true |